Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
Bioorg Chem. 2018 Dec;81:299-310. doi: 10.1016/j.bioorg.2018.08.013. Epub 2018 Aug 12.
New thiazolopyrimidine and dithiazolopyrimidinone derivatives 2-11 were synthesized and estimated for antimicrobial activity against S. aureus, B. cereus, E. coli, C. albicans, A. fumigatus and A. terreus. The attained results proved that 4, 8a and 11g have significant effectiveness against S. aureus and B. cereus. On the other hand, 7, 10b, 10c and 11h exhibited prominent activity against B. cereus, whereas 8a, 10b and 11g were proved to be active against E. coli. From another point of view, 4 and 8a exhibited promising efficacy against A. fumigatus and A. terreus; moreover, 8a showed outstanding efficacy against C. albicans. Quorum-sensing inhibitory activity of the new compounds was esteemed against C. violaceum, where 7, 8a, 9b, 10a-c, 11d and 11g have acceptable efficacy. In vitro antitumor efficacy of the same compounds against HepG2, HCT-116 and MCF-7 cancer cell lines was also tested. Compounds 4 and 11h showed enhanced effectiveness against the three cell lines, whereas 10b displayed eminent activity against HCT-116 and MCF-7 cells. Moreover, 11a was found to have outstanding activity against MCF-7 cells, while 11i showed promising efficacy against HepG2 cells. The in vitro active antitumor compounds were evaluated for in vivo antitumor effectiveness against EAC in mice, as well as in vitro cytotoxicity against WI38 and WISH normal cells. Results manifested that 4 has the strongest in vivo activity, and that all investigated analogs are less cytotoxic than 5-FU against both normal cell lines. DNA-binding affinity of the active compounds was examined, where 4, 8a, 10c, 11d and 11g,h displayed strong affinity. In silico studies proved that majority of the analyzed compounds are in conformity with the optimum needs for good oral absorption.
新噻唑并嘧啶和二噻唑并嘧啶酮衍生物 2-11 被合成并评估了对金黄色葡萄球菌、蜡状芽孢杆菌、大肠杆菌、白色念珠菌、烟曲霉和土曲霉的抗菌活性。所得结果证明,4、8a 和 11g 对金黄色葡萄球菌和蜡状芽孢杆菌具有显著的疗效。另一方面,7、10b、10c 和 11h 对蜡状芽孢杆菌表现出显著的活性,而 8a、10b 和 11g 对大肠杆菌表现出活性。从另一个角度来看,4 和 8a 对烟曲霉和土曲霉表现出有希望的疗效;此外,8a 对白色念珠菌表现出突出的疗效。新化合物的群体感应抑制活性也针对 C. violaceum 进行了评估,其中 7、8a、9b、10a-c、11d 和 11g 具有可接受的疗效。同样的化合物在体外对 HepG2、HCT-116 和 MCF-7 癌细胞系的抗肿瘤活性也进行了测试。化合物 4 和 11h 对这三种细胞系表现出增强的有效性,而 10b 对 HCT-116 和 MCF-7 细胞表现出突出的活性。此外,11a 被发现对 MCF-7 细胞具有突出的活性,而 11i 对 HepG2 细胞表现出良好的疗效。在体内对 EAC 进行了抗肿瘤活性评价,并在体外对 WI38 和 WISH 正常细胞进行了细胞毒性评价。结果表明,4 具有最强的体内活性,所有研究的类似物对两种正常细胞系的细胞毒性均低于 5-FU。还研究了活性化合物的 DNA 结合亲和力,其中 4、8a、10c、11d 和 11g、h 显示出很强的亲和力。计算机研究证明,大多数分析的化合物都符合良好口服吸收的最佳需求。